|Bid||2.00 x 500|
|Ask||3.15 x 10000|
|Day's Range||2.69 - 2.78|
|52 Week Range||1.63 - 30.00|
|PE Ratio (TTM)||0.14|
|Earnings Date||Nov 27, 2017 - Dec 1, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.00|
NEW YORK, NY / ACCESSWIRE / May 23, 2018 / U.S. markets fell Tuesday on geopolitical concerns after President Trump stated he was not happy with the current U.S. – China trade talks. The Dow Jones Industrial ...
Forward Pharma A/S (FWP) (“We” or “Forward” or the “Company”), today announced the filing of a notice of appeal of the decision of the Opposition Division of the European Patent Office (the “EPO”) that revoked EP2801355 (the “’355 patent”), written reasons for which were received on March 22, 2018. The notice was filed to the Technical Board of Appeal (the “TBA”) of the EPO. “With the notice of appeal filed, we officially initiate the process to get the decision of the Opposition Division overturned and have the ‘355 patent reinstated,” said Dr. Claus Bo Svendsen, Chief Executive Officer of Forward.
COPENHAGEN, Denmark, April 30, 2018-- Forward Pharma A/S, today reported financial results for the year ended December 31, 2017. Net income for the year ended December 31, 2017 was $917.1 million, or $2.30 ...
Research Desk Line-up: Forward Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 9, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for AVEO ...